Precision Medicine in AD: Castle’s New AdvanceAD-Tx Can Tell Which AD Patients Will Do Best on JAK inhibitors
Castle Biosciences, Inc. is launching AdvanceAD-Tx, a gene expression profile (GEP) test designed to guide systemic treatment decision-making in patients ages 12 and up with moderate-to-severe atopic dermatitis (AD). This 487-GEP test is designed to identify patients with a Janus kinase inhibitor (JAKi) responder profile who are more likely to achieve an Eczema Area and […]